Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 5.40M P/E - EPS this Y 65.20% Ern Qtrly Grth -
Income -10.63M Forward P/E -0.18 EPS next Y 47.20% 50D Avg Chg -10.00%
Sales 2.23M PEG - EPS past 5Y - 200D Avg Chg -82.00%
Dividend N/A Price/Book 15.00 EPS next 5Y - 52W High Chg -99.00%
Recommedations 2.00 Quick Ratio 0.37 Shares Outstanding 7.59M 52W Low Chg 11.00%
Insider Own 5.55% ROA -155.91% Shares Float 7.15M Beta 0.80
Inst Own 2.31% ROE - Shares Shorted/Prior 9.64K/17.48K Price 1.95
Gross Margin -240.17% Profit Margin - Avg. Volume 778,666 Target Price 11.25
Oper. Margin -612.72% Earnings Date Aug 8 Volume 71,458 Change -5.80%
About Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California.

Ensysce Biosciences, Inc. News
05/14/24 Ensysce Biosciences First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
05/13/24 Ensysce Biosciences Reports First Quarter 2024 Financial Results
05/13/24 ENSC: Quarterly Report Highlights Progress
04/25/24 Ensysce Biosciences’ CEO Dr. Lynn Kirkpatrick Featured in Xtalks Clinical Edge Magazine
04/19/24 Ensysce Biosciences' Presentation from the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference Published
04/09/24 Ensysce Biosciences to Participate in the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
03/15/24 ENSC Striding Toward Opioid Replacement
03/15/24 Ensysce Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results
02/27/24 Ensysce Biosciences Receives Positive Nasdaq Listing Determination
02/21/24 Ensysce Biosciences Announces Successful Meeting with FDA for PF614-MPAR, a Next Generation Opioid with Overdose Protection
02/16/24 ENSC: Investors Should Pay Attention
02/15/24 Ensysce Biosciences Announces Publication of Clinical Bioequivalence Manuscript
02/13/24 Ensysce Biosciences, Inc. Announces Exercise of Warrants for $4.7 Million Gross Proceeds
02/06/24 Ensysce Biosciences Selected to Present at American Association of Pain Medicine Annual Conference
01/31/24 Ensysce Biosciences Announces Positive End of Phase 2 Meeting with FDA for PF614 to Treat Severe Pain
01/25/24 Ensysce Biosciences to Present Groundbreaking Oral Overdose Protection for Opioids at the 5th Annual NIH HEAL Meeting
01/23/24 Opioid Developer Ensysce Biosciences Stock Is Shooting Higher Today - Here's Why
01/23/24 Ensysce Biosciences Announces FDA Breakthrough Therapy Designation Granted for PF614-MPAR
01/23/24 ENSC Announces Major FDA Designation
01/08/24 Ensysce Biosciences Issues 2024 Shareholder Letter
ENSC Chatroom

User Image HeisenbergCT Posted - 4 hours ago

$ENSC ..."you know that something needs to happen.".. I click on many stock articles and websites, and I take them all with a grain of salt. Whether it's an analyst op/ed, or Joe couch potato, I'm typically skeptical and never take recommendations too seriously. I keep an eye out for articles that are different and articles that educate -- like this. Gives some great insight I haven't found before quite like the way the author lays it out here. I'm not endorsing the site. I simply like what I read on this page. **Special attention to #2** ... the most relevant to ENSC: https://www.sickeconomics.com/2019/01/25/3-signs-biotech-acquired/

User Image alejajcucha Posted - 9 hours ago

$ENSC when $15?? 🚀🚀🚀

User Image never_give_up Posted - 1 day ago

$ENSC added at 0.56 a few days ago

User Image kilo1212 Posted - 1 day ago

$ENSC even with fda fast tract for TAAP is there to much red tape for this take hold in the pharmaceutical industry without all the opioid makers being on board to change there manufacturing of opioid product. Can the FDA mandate using TAAP ingredient in all future opioids. If so ENSC is sitting on a gold mine.

User Image shift_4 Posted - 1 day ago

$ENSC added, as usual

User Image martinejwrx Posted - 1 day ago

$ENSC don’t move a muscle 💪, everyone is holding tight!

User Image HeisenbergCT Posted - 1 day ago

$ENSC with competition often with 100+ billion dollar valuations, I would consider an early buyout if offered and the price is right. They've been putting this together since 2009, they're not in their 30's and no guarantee the mega caps won't drain the talent away from Ensysce with more lucrative contracts. CEO L.KirkPatrick has at least one acquisition in her professional past and while not likely at this point, it's not unprecedented either. I'm willing to vote yes on $80 per share. It's not the $246 I want but $80 is a nice chunk I can certainly live with.. . Of course all speculation. That's all we can do during this curious long stretch with no news on the clinical trial front -- not even a listing confirmation which we got the DAY AFTER the last 2 occasions the company successfully met such a deadline. Could be nothing or normal before the start of phase 3. Could be something huge brewing too, like a deal. What's behind curtain #3? ...as always, time will tell. good weekend!

User Image Tshanky_ Posted - 1 day ago

$ENSC $SGMO Completely different market caps, but similar charts. Added more of both of them yesterday AM

User Image IOnlyTradeForGreen Posted - 1 day ago

$ENSC A legit once in a lifetime gem right here. LOAD THE BOAT and be patient… or sit on the sidelines and miss an opportunity like buying Bitcoin at a dollar.

User Image HeisenbergCT Posted - 1 day ago

$ENSC May 9 filing by Ensysce: "....the Company thereafter presented a compliance plan to the Nasdaq Hearings Panel, which granted the Company an extension THROUGH May 13, 2024, to evidence compliance with the Rule." ...." The Company AWAITS Nasdaq’s formal confirmation regarding the Company’s compliance status." May 17 and still waiting for that confirmation

User Image HeisenbergCT Posted - 1 day ago

$ENSC the global opioid market was estimated to be $22 BILLION in 2022, and that number is rising fast. In 2021 three companies, including Johnson & Johnson who is currently following Ensysce on X, were forced to pay $26 BILLION in settlements claiming they helped fuel the opioid crisis. The stakes in this space are enormous. For those who see my PT of $246 and doubt it when compared to $0.63, they simply have no idea what's at stake. $246 p/share would still put ENSC below a $2 BILLION valuation. If they make it out of trials, it will be the first alternative opioid developed in DECADES and the only one with abuse/overdose protection. Even if the competition manages to bring their similar drugs to market, ENSC would still be a unique and formidable player. You can argue zero - always a risk in bio. You can't argue this share price stops at $5, $20, or $50. ***There's no plausible case for that scenario based on the size of the market their drug(s) would disrupt.*** $246

User Image BULLISH1975 Posted - 1 day ago

$ENSC

User Image Bigdogg501 Posted - 1 day ago

$ENSC we are heating up something most definitely cooking

User Image BULLISH1975 Posted - 1 day ago

@mrinvestorpro you have some good picks wow! wish i had got FFIE. i have NUWE. love ur thoughts on $ENSC! shorted to hell. no debt. MC about 5 million. Volume more than doubled last 4 days. Near all time lows. one phase III trial starting soonH2. they received BTD for their phase I drug recently. they have an equivalent opioid to Oxycodene which cannot be tampered with and people cannot OD from. Revolutionary IMO! shorts have been fucking it for years. primed to have huge move IMO! they can also control release so only two doses a day. Love your thoughts dyor

User Image mrsparex Posted - 2 days ago

$ENSC I'm surprised this board isn't busier... ... oh well! At least we're getting a little "green".

User Image SwissCherry69 Posted - 2 days ago

$BDRX $BONE $BJDX $ENSC $VIRI If phase 2 results are good. Tuesday we could see a huge run to + 10 USD 🍋🤞

User Image ChiefOG Posted - 2 days ago

$ENSC stay tuned here

User Image NEWBIGTECH Posted - 2 days ago

$ESPR great moves on $ESPR $ENSC $ICU . Remember the shorts took these down, now set your sells higher than the ask and make the shorts pay to cover. It's not rocket science!

User Image geumrivale Posted - 2 days ago

$ENSC $INM and $LGHL chart and low float.

User Image SwissCherry69 Posted - 2 days ago

$BDRX update phase 2 next Thuesday for BDRX. Stay focus!🔥💰👍🍋 $BONE $BJDX $ENSC $VIRI

User Image Callmedaddy2 Posted - 2 days ago

$ENSC looks like the reversal is continuing. If we hit close to $1 before phase 3 is announced this will go parabolic 🤩

User Image BULLISH1975 Posted - 2 days ago

$ENSC $ICU ensc on the move slowly ! i think its going to rerate huge imo.

User Image Tshanky_ Posted - 2 days ago

$ENSC

User Image geumrivale Posted - 2 days ago

@MKRReformed $ensc just starting

User Image SmallCapGrowth Posted - 2 days ago

$ENSC Ensysce Biosciences First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag https://finance.yahoo.com/news/ensysce-biosciences-first-quarter-2024-104917938.html

User Image Tshanky_ Posted - 2 days ago

$SGMO $ENSC I think these both move soon. Both creeped up from .50

User Image BULLISH1975 Posted - 2 days ago

$ENSC - I am not a technical trader but this looks juicy! -MC less than 5 million. -No debt -About 2 million cash -Starting a phase III 2h in 2023 -Received BTD for their phase I a few weeks ago. -Founder bought about 1 million worth of shares about 18 months ago at about $7. -Looks ready to pop IMO!!!! $GME $FFIE

User Image BULLISH1975 Posted - 2 days ago

$ENSC We just need half your followers to buy 5000 today and we off to the races :-0)

User Image Tshanky_ Posted - 2 days ago

$ENSC slapped

User Image SmallCapGrowth Posted - 2 days ago

Breakout Alert: Ensysce Biosciences, Inc. (NASDAQ: ENSC) Multiple potential near-term catalysts. See the full analysis below. >>> Click here for the full $ENSC analysis https://broadstreetalerts.com/wp-content/uploads/2024/05/BSA-ENSC-Analysis-5-15-24.pdf $GME $MPW

Analyst Ratings
HC Wainwright & Co. Buy Sep 25, 23
HC Wainwright & Co. Buy Jul 3, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
GOWER BOB G Director Director Feb 28 Buy 0.48 379,300 182,064 1,132,395 03/02/23
GOWER BOB G Director Director Dec 09 Buy 1.40 357,143 500,000 753,095 02/01/23
Kirkpatrick Lynn Chief Executive Offi.. Chief Executive Officer May 25 Buy 0.51 97,000 49,470 381,851 05/27/22